DrugPatentWatch Database Preview

Sun Pharm Inds Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?

SUN PHARM INDS has two hundred and twelve approved drugs.

There are twelve US patents protecting SUN PHARM INDS drugs. There are four tentative approvals on SUN PHARM INDS drugs.

There are forty-two patent family members on SUN PHARM INDS drugs in twenty-three countries and one hundred and ninety supplementary protection certificates in sixteen countries.

Summary for Sun Pharm Inds

International Patents:	42
US Patents:	12
Tradenames:	156
Ingredients:	145
NDAs:	212

Drugs and US Patents for Sun Pharm Inds

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds	CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY	fexofenadine hydrochloride	TABLET;ORAL	091567-002	Feb 6, 2012		OTC	No	No
Sun Pharm Inds Inc	HYDROCODONE BITARTRATE AND IBUPROFEN	hydrocodone bitartrate; ibuprofen	TABLET;ORAL	091633-002	May 28, 2013		DISCN	No	No
Sun Pharm Inds	OLANZAPINE	olanzapine	TABLET;ORAL	091038-001	Apr 23, 2012	AB	RX	No	No
Sun Pharm Inds Ltd	LETROZOLE	letrozole	TABLET;ORAL	091466-001	Jun 3, 2011		DISCN	No	No
Sun Pharm Inds Inc	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012		RX	No	No	7,541,347
Sun Pharm Inds Ltd	QUINAPRIL HYDROCHLORIDE	quinapril hydrochloride	TABLET;ORAL	090800-003	Jun 18, 2009		DISCN	No	No
Sun Pharm Inds Inc	CLONIDINE HYDROCHLORIDE	clonidine hydrochloride	TABLET;ORAL	090329-001	Jul 3, 2014		DISCN	No	No

Expired US Patents for Sun Pharm Inds

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	ULTRAVATE	halobetasol propionate	OINTMENT;TOPICAL	019968-001	Dec 17, 1990	4,619,921
Sun Pharm Inds Inc	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-001	Jul 11, 2012	5,908,838
Sun Pharm Inds Inc	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-005	Jul 11, 2012	5,908,838
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982	3,551,564
Sun Pharm Inds Inc	LAC-HYDRIN	ammonium lactate	LOTION;TOPICAL	019155-001	Apr 24, 1985	4,105,783
Sun Pharm Inds Inc	XIMINO	minocycline hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	201922-003	Jul 11, 2012	5,908,838
Sun Pharm Inds Inc	ULTRAVATE	halobetasol propionate	CREAM;TOPICAL	019967-001	Dec 27, 1990	4,619,921

Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	20 mg		2013-01-07
	Capsules	35 mg		2015-11-25
	Capsules	30 mg and 40 mg		2012-12-31
	Capsules	20 mg		2013-06-19
	Capsules	25 mg		2016-05-16

International Patents for Sun Pharm Inds Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2964195
China	1635881
Brazil	102013032172
South Africa	200300990
Canada	2836228
Australia	2006262428
Germany	60104206

Supplementary Protection Certificates for Sun Pharm Inds Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	PA2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
1506211	179 5017-2014	Slovakia		PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
1261586	15/2012	Austria		PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
1506211	122014000071	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sun Pharm
• Sun Pharm Inds
• Sun Pharm Inds (in)
• Sun Pharm Inds Inc
• Sun Pharm Inds Ltd
• Sun Pharm Industries
• Sun Pharma Global